Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount

Menarini Remains In Front

 
• By Andrew McConaghie
Sanofi
The failure is a blow to Sanofi's hopes of expanding its presence in oncology. • Source: Shutterstock

More from Business

More from Scrip